Evidence map›Paper›PMID 23486238›Full record

ReviewNature reviews. Cancer2013

The effects of PEDF on cancer biology: mechanisms of action and therapeutic potential.

S Patricia Becerra, Vicente Notario

Open access · greenAbstract readReview
In one paragraph

Review in Nature reviews. Cancer, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 126 papers.

0numbers the graph read from it
0cells of the map it votes in
126citing papers in PubMed
10.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

126 citing papers in PubMed, 210 citations in OpenAlex.

  1. Trial
  2. Effect of a 12-month exercise intervention on serum biomarkers of angiogenesis in postmenopausal women: a randomized controlled trial.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2014
    Trial
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Nuclear destabilisation - a possible genesis of cancer?Biological reviews of the Cambridge Philosophical Society · 2025
    Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

66 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

S Patricia BecerraNational Eye Institute, US National Institutes of Health, Bethesda, Maryland, USA. becerrap@nei.nih.gov
Vicente Notario
Georgetown University Medical Center · USNational Institutes of Health · US

Funding

Role of Protein Interactions in Retina Development and FunctionZIAEY000306 · NEI · NATIONAL EYE INSTITUTE · PI BECERRA, S. PATRICIA · 2009 to 2025
$15.6M
Targeting EWS/FLI1-driven pathways to improve therapeutic gains in Ewing's SarcomR01CA134727 · NCI · GEORGETOWN UNIVERSITY · PI NOTARIO, VICENTE · 2008 to 2012
$1.6M
Intramural NIH HHS ZIA EY000306NCI NIH HHS R01 CA134727NCI NIH HHS R01‑CA134727NEI NIH HHS 1ZIA‑EY000306
6 · The paper itself

Abstract

The potent actions of pigment epithelium-derived factor (PEDF) on tumour-associated cells, and its extracellular localization and secretion, stimulated research on this multifunctional serpin. Such studies have identified several PEDF receptors and downstream signalling pathways. Known cellular PEDF responses have expanded from the initial discovery that PEDF induces retinoblastoma cell differentiation to its anti-angiogenic, antitumorigenic and antimetastatic properties. Although the diversity of PEDF activities seems to be complex, they are consistent with the varied mechanisms that regulate this multimodal factor. If PEDF is to be used for cancer management, a deeper appreciation of its many functions and mechanisms of action is needed.

Indexed as

Angiogenesis InhibitorsCell DifferentiationEye ProteinsHumansNeoplasmsNerve Growth FactorsPigment Epithelium-Derived FactorProtease InhibitorsSerpinsAngiogenesis InhibitorsEye ProteinsNerve Growth FactorsPigment Epithelium-Derived FactorProtease InhibitorsSerpins

Identifiers

PMID23486238
PMCPMC3707632
OpenAlexW2086690729

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.